Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Stephen Baxter
WF

Stephen Baxter

Wells Fargo
Wall Street Analyst
★★★★★
#133
on 13Foresight · ranked by our own returns
68%
Success Rate
+7.7%
Average Return
70 of 103 calls profitable · +5.5% vs benchmark
S&P 500 (SPY)
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 68% of Stephen Baxter's ratings turned a profit when each position was held for 1 year — averaging +7.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

89 Buy 65 Hold 9 Sell
Stephen's Stock Coverage 28 ratings · 2026-11-06
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
CNC
Centene
 Oct 30, 2026 HOLD Buy
+7.4% avg upside
29 analysts
$75.00
9.58% Upside
 +1.9% ·
MOH
Molina Healthcare
 Oct 29, 2026 HOLD Buy
+16.5% avg upside
26 analysts
$220.00
7.39% Upside
 +8.9% ·
UHS
Universal Health
 Oct 27, 2026 HOLD Buy
+8.4% avg upside
22 analysts
$166.00
5.67% Downside
 +10.2% ·
UNH
UnitedHealth
 Oct 27, 2026 BUY Strong Buy
+12.6% avg upside
36 analysts
$487.00
19.59% Upside
 -4.0% ·
HCA
HCA Healthcare
 Oct 27, 2026 HOLD Buy
-11.8% avg upside
37 analysts
$381.00
19.44% Downside
 +10.0% ·
ELV
Elevance Health
 Oct 27, 2026 BUY Strong Buy
+10.7% avg upside
33 analysts
$492.00
17.13% Upside
 +1.0% ·
CI
Cigna
 Sep 30, 2026 HOLD Strong Buy
+15.7% avg upside
30 analysts
$307.00
2.87% Upside
 +12.3% ·
OSCR
Oscar Health
 Sep 16, 2026 HOLD Buy
-10.1% avg upside
16 analysts
$27.00
11.12% Downside
 +2.6% ·
HUM
Humana
 Sep 15, 2026 BUY Strong Buy
+5.9% avg upside
34 analysts
$502.00
21.10% Upside
 +9.6% ·
CVS
CVS Health
 Sep 15, 2026 BUY Strong Buy
+19.5% avg upside
39 analysts
$123.00
36.36% Upside
 -12.9% ·
CAH
Cardinal Health
 Sep 09, 2026 BUY Strong Buy
-14.3% avg upside
30 analysts
$277.00
10.58% Upside
 +13.2% ·
LMRI
Lumexa Imaging Holdings, Inc.
 Aug 14, 2026 BUY Strong Buy
+66.2% avg upside
10 analysts
$19.00
66.59% Upside
 -5.1% ·
CON
Concentra Group Holdings Parent, Inc.
 Aug 11, 2026 BUY Strong Buy
+0.7% avg upside
14 analysts
$40.00
0.91% Downside
 +32.6% ·
COR
Cencora
 Aug 11, 2026 BUY Buy
-2.6% avg upside
45 analysts
$395.00
19.49% Upside
 +5.4% ·
MCK
McKesson
 Aug 11, 2026 HOLD Strong Buy
-20.4% avg upside
29 analysts
$933.00
6.24% Downside
 +17.8% ·
MDLN
Medline
 Aug 11, 2026 HOLD Strong Buy
+43.4% avg upside
27 analysts
$34.00
5.84% Upside
 +13.1% ·
AGL
Agilon Health
 Aug 10, 2026 BUY Buy
-18.0% avg upside
26 analysts
$146.00
71.93% Upside
 -2.0% ·
PNTG
Pennant Group
 Aug 10, 2026 BUY Strong Buy
-11.2% avg upside
9 analysts
$46.00
10.41% Upside
 -7.4% ·
BTSG
BrightSpring Health Services, Inc.
 Aug 03, 2026 BUY Strong Buy
-0.5% avg upside
20 analysts
$78.00
16.65% Upside
 +8.9% ·
THC
Tenet Healthcare
 Jul 31, 2026 BUY Strong Buy
-9.6% avg upside
29 analysts
$281.00
2.79% Upside
 +12.4% ·
CYH
Community Health
 Apr 27, 2026 SELL Sell
+66.3% avg upside
20 analysts
$2.00
16.72% Downside
 +27.1% ·
TDOC
Teladoc
 Oct 29, 2025 HOLD Buy
+241.7% avg upside
38 analysts
$8.00
5.97% Downside
 +6.1% ·
AMWL
American Well
 May 01, 2024 HOLD Hold
+26.3% avg upside
15 analysts
$40.00
214.16% Upside
 -41.7% ·
LH
Labcorp Holdings
 Jan 11, 2021 HOLD Strong Buy
-21.6% avg upside
38 analysts
$235.00
34.88% Downside
 +34.5% ·
MEDP
Medpace Holdings
 May 13, 2020 HOLD Buy
-17.3% avg upside
18 analysts
$91.00
86.03% Downside
 +99.7% ·
DGX
Quest Diagnostics
 Apr 27, 2020 HOLD Buy
-26.4% avg upside
34 analysts
$116.00
54.00% Downside
 +16.2% ·
CRL
Charles River Labs
 Feb 18, 2020 BUY Strong Buy
-28.4% avg upside
36 analysts
$203.00
43.61% Downside
 +66.3% ·
IQV
IQVIA Holdings
 Nov 14, 2019 BUY Strong Buy
-2.5% avg upside
40 analysts
 — +19.4% ·
🔒 23 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Stephen Baxter — Frequently Asked Questions
How accurate are Stephen Baxter's stock ratings?
Based on the calls 13Foresight could measure, about 67% of Stephen's ratings were profitable over a one-year hold, with an average return of +7.5% per rating, or +4.5% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Stephen ranked on 13Foresight?
Stephen Baxter is currently ranked #133 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Stephen cover?
Stephen most recently has ratings on CNC, MOH, UHS, UNH, HCA, ELV, CI, OSCR, HUM, CVS, CAH, LMRI and 16 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.